Global Mesalamine Market Research Report 2021

Mesalamine, also known as Mesalamine, or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
The industry's leading manufacturers are Syntese A/S, Divis Laboratories, ipca Laboratories and Cambrex Corporation, which accounted for 23.74%, 14.71%, 6.44% and 6.35% of the global revenue share in 2019, respectively.
In terms of regions, the revenue share of Europe is the highest, reaching 41.11% in 2019.

The global Mesalamine market was valued at US$ 136.5 million in 2019 and is expected to reach US$ 183.2 million by the end of 2026, growing at a CAGR of 3.2% during 2021-2026.
This report focuses on Mesalamine volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Mesalamine market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Mesalamine Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Purity ≥ 97%
Purity ≥ 98%
Purity ≥ 99%
According to the type, Mesalamine whose Purity ≥ 99% accounted for the largest global revenue share with 43.73% in 2019.

Segment by Application
Mesalazine Tablets
Mesalazine Capsules
Others
Mesalazine Tablets took the largest market share in terms of volume, with 42.15% in 2019.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Syntese A/S
Divis Laboratories
Cambrex Corporation
Ipca Laboratories
Hangzhou Brother
PharmaZell
Lianyungang Fengheng Biopharm
Lasa Loboratory
Erregierre SpA
Corden Pharma Bergamo
CTX Lifescience
Ishita Active Pharma Ingredients
YC Biotech (Jiangsu)
Xinxiang Tianfeng Fine Chemical

Frequently Asked Questions